ALK and cancer: Some of the reported mechanisms underlying the acquired resistance to crizotinib in ALK translocated cancers involve secondary mutations, ALK amplification, KIT amplification, and autophosphorylation of epidermal growth factor receptor (EGFR) (9–13).